Pharmaceuticals

As CEO Gareth Sheridan takes the stage, his company's abuse-deterrent tech, AVERSA™, promises a new front in the opioid crisis. But can it deliver?

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

Journey Medical posts a stellar 23% revenue jump, nearing profitability. But beyond the headlines, a crucial SEC filing reveals a complex financial reality.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.

Beyond the headlines of consolidation, an invisible digital and logistical network is empowering independent medical clinics. Here’s how it works.

A Chinese firm's historic USFDA approval for a complex generic drug ingredient signals a major shift in the global pharma supply chain and promises cheaper medicines.

A new partnership is bringing advanced, U.S.-based manufacturing to a rare cancer drug, aiming to solve daily patient challenges and bolster national supply chains.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

A new partnership aims to bring the first FDA-approved, oral ketamine pill for depression to your home, using AI and real-world data to ensure safety.

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

COSCIENS Biopharma boasts a dramatic financial turnaround, but its strategic move to exit SEC oversight shifts the risk-reward calculus for investors.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

A novel dual-action antibody shows remarkable durability in Phase 2 trials, offering a potential six-month dosing schedule for millions with chronic sinusitis.

A new report reveals undiagnosed testosterone deficiency could cost the U.S. up to $525 billion, but the real story is about the millions of men being missed.

Quebec's funding for Roche's Itovebi offers new hope for breast cancer patients, but its complex approval reveals a national struggle over drug costs and access.

A new platform offers physicians 24/7 access to 'lifelike' AI pharma reps. We analyze the tech, the immense regulatory risks, and the potential to level the playing field.